Skip to main content
SpringerLink
Log in

Adefovir Dipivoxil

Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Gilead Sciences Inc. Gilead initiates early access program for adefovir dipivoxil, investigational treatment for chronic hepatitis B infection. Media Release.: [3 pages], 12 Mar 2002. Available from: URL: http://www.gilead.com

    Google Scholar 

  2. Cundy KC, Fishback JA, Shaw J-P, et al. Oral bioavailability of the antiretroviral agent 9-(2- phosphonylmethoxyethyl) adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res 11: 839–843, Jun 1994

    Article  PubMed  CAS  Google Scholar 

  3. Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2- (bis-pivaloyloxymethyl)- phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 176: 406–413, Aug 1997

    Article  PubMed  CAS  Google Scholar 

  4. Barditch-Crovo PA, Cundy KC, Wachsman M, et al. Pharmacokinetic profile of 9-[2-(bispivaloyloxy-methyl) phosphonylmethoxy] adenine (bis-POM PMEA), an orally bioavailable prodrug of the antiviral nucleotide, PMEA. 2nd National Conference Human Retroviruses and Related Infections: 145, 29 Jan 1995. USA

    Google Scholar 

  5. Cundy KC, Barditch-Crovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 39: 2401–2405, Nov 1995

    Article  PubMed  CAS  Google Scholar 

  6. Noble S, Goa KL. Adefovir dipivoxil. Drugs. 58: 479–487, Sep 1999

    Article  PubMed  CAS  Google Scholar 

  7. Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 176: 1517–1523, Dec 1997

    Article  PubMed  CAS  Google Scholar 

  8. Gilead Sciences Inc. Gilead Sciences announces statistically significant data from phase II/III study of Preveon for the treatment of patients with HIV infection. Media Release: [3 pages], 6 Apr 1998

    Google Scholar 

  9. Kahn J, Lagakos S, Weng D, et al. A multi-center, randomized, double-blind placebo controlled study of the efficacy and safety of adefovir dipivoxil when added to standard antiretroviral therapy. AIDS. 12 (Suppl 4): 13, Nov 1998

    Google Scholar 

  10. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS. 15: 1695–1700, 7 Sep 2001

    Article  PubMed  CAS  Google Scholar 

  11. Zídek Z, Hol A, Franková D, et al. Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs. Eur J Pharmacol 286: 307–310, 24 Nov 1995

    Article  PubMed  Google Scholar 

  12. Naesens L, Neyts J, Balzarini J, et al. Antiviral efficacy in mice of oral bis(POM)-PMEA, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res 26: A276, Mar 1995

    Article  Google Scholar 

  13. Mulato AS, Lamy PD, Miller MD, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 42: 1620–1628, Jul 1998

    PubMed  CAS  Google Scholar 

  14. Gilead Sciences Inc. Gilead Sciences announces data from clinical study of Preveon in combination with other anti-HIV agents in treatment-naive patients. Media Release: [2 pages], 6 Apr 1998

    Google Scholar 

  15. Kahn JO, Lagakos S, Weng D, et al. Amulti-center, randomized, double-blind placebo controlled study of the efficacy and safety of adefovir dipivoxil when added to standard antiretroviral therapy. 12thWorld AIDS Conference Supplement: 6, 28 Jun 1998

    Google Scholar 

  16. Gilead Sciences provides update on Preveon clinical program for the treatment of HIV; Preveon profile to be highlighted in five oral presentations at ICAAC Conference. BW HealthWire [online]: [3 pages], 24 Sep 1998. Available from URL: http://www.newspage.com

  17. Miller MD, Margot NA, Lamy PD, et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr 27: 450–458, 15 Aug 2001

    PubMed  CAS  Google Scholar 

  18. Gilead Sciences Inc. Gilead Sciences announces preliminary results from studies of PREVEON 60 mg for HIV infection. Media Release: [3 pages], 4 Mar 1999. Available from URL: http://www.gilead.com

    Google Scholar 

  19. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. J Am Med Assoc 282: 2305–2312, 22–29 Dec 1999

    Article  CAS  Google Scholar 

  20. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatmentexperienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr 23: 221–226, 1 Mar 2000

    PubMed  CAS  Google Scholar 

  21. Gilson RJC, Chopra K, Murray-Lyon I, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patientswith chronic hepatitis B infection. Hepatology. 24 (Program Suppl): 281, Part 2, Oct 1996

    Google Scholar 

  22. Gilson RJC, Murray-Lyon IM, Nelson MR, et al. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology. 28 (Suppl): 491, Part 2, Oct 1998

    Article  Google Scholar 

  23. Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology. 28 (Suppl): 317, Part 2, Oct 1998

    Google Scholar 

  24. Eison R, Dieterich D, Weisz K, Goldman D. Adefovir and abacavir combination therapy for chronic HBV: three case reports of successful treatment. Gastroenterology. 116: 705 (Poster), Part 2, Apr 1999

    Google Scholar 

  25. Gilson RJC, Chopra KB, Newell AM, et al. Aplacebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatitis 6: 387–395, Sep 1999

    Article  CAS  Google Scholar 

  26. Gilead Sciences Inc. Gilead achieves primary endpoint in phase III study of adefovir dipivoxil for chronic hepatitis B virus infection. Media Release: [4 pages], 22 Jun 2001. Available from URL: http://www.gilead.com

    Google Scholar 

  27. Gilead Sciences Inc. Gilead Science announces results from phase III study of adefovir dipivoxil in precore mutant chronic hepatitis B virus infection. Media Release: [5 pages], 20 Sep 2001. Available from URL: http://www.gilead.com

    Google Scholar 

  28. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32: 129–134, Jul 2000

    Article  PubMed  CAS  Google Scholar 

  29. Chung RT, Contreras AM, Baid S, et al. Low-dose immunosuppression is associated with narrowing of HCV quasispecies diversity following liver transplantation. Hepatology. 32: 260, Part 2, Oct 2000

    Google Scholar 

  30. Gilead Sciences Inc. Gilead announces primary endpoint met in phase III study of adefovir dipivoxil 10 mg in patients with lamivudine-resistant chronic hepatitis B infection. Media Release: [4 pages], 9 Nov 2001. Available from URL: http://www.gilead.com

    Google Scholar 

  31. Benhamou Y, Bochet M, Thibault V, et al. An open label pilot study of the safety and efficacy of adefovir dipivoxil in HIV/HBV co-infected patients with lamivudine resistant HBV. Hepatology 32: 459, Part 2, Oct 2000

    Google Scholar 

  32. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 358: 718–723, 1 Sep 2001

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adefovir Dipivoxil. Drugs R&D 3, 178–187 (2002). https://doi.org/10.2165/00126839-200203030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00008

Keywords

Search

Navigation